Belgía - þýska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline pharmaceuticals - epoprostenol-natrium - pulver und lösungsmittel zur herstellung einer infusionslösung - 0,5 mg - epoprostenol-natrium - epoprostenol

Belgía - þýska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline pharmaceuticals - epoprostenol-natrium - pulver und lösungsmittel zur herstellung einer infusionslösung - 1,5 mg - epoprostenol-natrium - epoprostenol

Belgía - þýska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline pharmaceuticals - epoprostenol-natrium - pulver zur herstellung einer infusionslösung - 1,5 mg - epoprostenol-natrium - epoprostenol

Belgía - þýska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline pharmaceuticals - epoprostenol-natrium - pulver und lösungsmittel zur herstellung einer infusionslösung - 0,5 mg - epoprostenol-natrium - epoprostenol

Belgía - þýska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline pharmaceuticals - epoprostenol-natrium - pulver zur herstellung einer infusionslösung - 0,5 mg - epoprostenol-natrium - epoprostenol

Sviss - þýska - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - gemtuzumabum ozogamicinum - pulver für ein konzentrat zur herstellung einer infusionslösung - gemtuzumabum ozogamicinum 5 mg, saccharum, dextranum 40, natrii chloridum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, pro vitro corresp. natrium 12.54 mg. - akute myeloische leukämie - biotechnologika

Evrópusambandið - þýska - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - multiples myelom - antineoplastische mittel - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Evrópusambandið - þýska - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - multiples myelom - antineoplastische mittel - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Evrópusambandið - þýska - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anämie, sichelzellen - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Evrópusambandið - þýska - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastische mittel - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).